Jeremy D. Jokinen

Jeremy D. Jokinen

Auto-generated profile, based on publicly available information

Jeremy D. Jokinen

Bristol Myers Squibb, Lawrenceville, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
JTJames Toouli
James Toouli
LKLillian Kow
Lillian Kow
ARAlmino C. Ramos
Almino C. Ramos
FAFranz Aigner
Franz Aigner
PPPiet Pattyn
Piet Pattyn
JJJeremy Jokinen
Jeremy Jokinen

12 June 2019 in Drug Safety
Verified
Journal Article
Open access
PDF file
JJJeremy D. Jokinen
Jeremy D. Jokinen
RWRosalind J. Walley
Rosalind J. Walley
MCMichael W. Colopy
Michael W. Colopy
THThomas S. Hilzinger
Thomas S. Hilzinger
PVPeter Verdru
Peter Verdru
The volume of adverse events (AEs) collected, analysed, and reported has been increasing at a rapid rate for over the past 10 years, largely due to the growth of solicited programmes. The proportion of various forms of solicited case data has evolved over time, with the main relative volume increase coming from Patient Support Programmes. In this study, we sought to examine the impact of the pooling of AE report data from solicited sources with data from spontaneous sources to safety signal detection using disproportionality analysis methods.

1 November 2019 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
JJJeremy Jokinen
Jeremy Jokinen
DBDominique Bertin
Dominique Bertin
BDBruce Donzanti
Bruce Donzanti
JHJanet Hormbrey
Janet Hormbrey
VSValerie Simmons
Valerie Simmons
PVPeter Verdru
Peter Verdru
Over the past decade, the volume of adverse events (AEs) reported to marketing authorization holders and regulators has been rapidly increasing each year, which has led to significant challenges in patient safety assessment. Three data sources that have largely contributed to the expansion in adverse event reports are patient support programs (PSPs), market research programs (MRPs), and social media. In this study, we sought to further understand the contribution of these safety data sources to the characterization of a product’s safety profile. Three separate approaches were taken that, when combined, can be used to evaluate each data source. The first identified any core company data sheet changes or drug safety label changes. The second evaluated the similarity of information through proportions of AEs between each solicited data source and spontaneous sources. Lastly, the completeness of information reported was evaluated through vigiGrade and compared across each data source. One drug safety label change was identified from a patient support program, which involved regular contact with health care providers. No label changes were identified from market research programs or social media. Patient support programs, market research programs, and social media report similar proportions for HLGT as spontaneous sources. Market research programs and social media display very low vigiGrade scores. When broken down by subtype, traditional PSPs display high vigiGrade scores, while patient assistance programs display lower vigiGrade scores that were program dependent. This study did not demonstrate that certain data sources such as market research programs, social media, and patient assistance programs meaningfully contributed to the further understanding of the characterization of a product’s safety profile.

27 July 2020 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
ILInyoung Lee
Inyoung Lee
TLTodd A. Lee
Todd A. Lee
SCStephanie Crawford
Stephanie Crawford
RKRyan D. Kilpatrick
Ryan D. Kilpatrick
GCGregory Sampang Calip
Gregory Sampang Calip
JJJeremy D. Jokinen
Jeremy D. Jokinen
Marketing authorization holder (MAH)-sponsored patient support programs (PSPs) are a major source of adverse event (AE) reports. The impact of reports from PSPs on the ability to detect AE signals is unclear. The authors compared signal detection performance using data from PSPs vs. non-PSP sources, and between PSPs providing clinical services vs. PSPs not providing clinical services. Data were obtained from an internal safety database for a global pharmaceutical company 2015-2017. The authors assessed whether signals were detected for the reference drug-AE pairs using data from PSPs vs. non-PSP sources, and among different PSP services. Performance was evaluated by four measures including area under the receiver operating characteristics curve (AUC) and time-to-signal detection. While the majority of reports were from PSPs, non-PSP sources were better and faster at detecting signals (AUC 0.63 vs. 0.41, p=0.035; HR 3.52, p=0.014) compared to PSPs. Within PSPs, PSPs providing clinical services were marginally better at detecting signals (AUC 0.60 vs. 0.41, p=0.053) but not faster compared to PSPs not providing clinical services. Reports of AEs from PSPs had worse signal detection performance compared to non-PSP sources. Pharmacovigilance experts should be mindful when using databases that contain reports from PSPs for signal detection.

27 July 2020 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Closed access
PDF file
ILInyoung Lee
Inyoung Lee
JJJeremy D. Jokinen
Jeremy D. Jokinen
SCStephanie Crawford
Stephanie Crawford
GCGregory Sampang Calip
Gregory Sampang Calip
RKRyan D. Kilpatrick
Ryan D. Kilpatrick
TLTodd A. Lee
Todd A. Lee

1 August 2004 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
KKKari T. Korttila
Kari T. Korttila
JJJeremy D. Jokinen
Jeremy D. Jokinen